Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
30 August 2021Website:
http://scisparc.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 22:35:48 GMTDividend
Analysts recommendations
Institutional Ownership
SPRC Latest News
FDA confirm s that SciSparc's study may proceed only a month after application submission
The intended selling valuation represents an increase of 47 % from the valuation at the time of SciSparc's initial investment in MitoCareX Bio
FDA confirm s that SciSparc's study may proceed following the application submission a month ago
Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial
This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of its patent application under the international Patent Cooperation Treaty, for innovative combinations of ketamine and N-acylethanolamines.
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center , Jerusalem , Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of the IASLC
- 1(current)
What type of business is SciSparc?
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
What sector is SciSparc in?
SciSparc is in the Healthcare sector
What industry is SciSparc in?
SciSparc is in the Biotechnology industry
What country is SciSparc from?
SciSparc is headquartered in Israel
When did SciSparc go public?
SciSparc initial public offering (IPO) was on 30 August 2021
What is SciSparc website?
https://scisparc.com
Is SciSparc in the S&P 500?
No, SciSparc is not included in the S&P 500 index
Is SciSparc in the NASDAQ 100?
No, SciSparc is not included in the NASDAQ 100 index
Is SciSparc in the Dow Jones?
No, SciSparc is not included in the Dow Jones index
When was SciSparc the previous earnings report?
No data
When does SciSparc earnings report?
Next earnings report date is not announced yet